This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
AhlskogJE,UittiRJ(2010):Rasagiline,Parkinsonneuroprotection,anddelayed-starttrials:stillnosatisfaction?Neurology74:1143–1148
BirkmayerW,HornykiewiczO(1961):DerL-Dioxyphenylalanin(L-DOPA)EffektbeiderParkin-son-Akinese.WienklinWschr.78:787–788
ChenJJ,SwopeDM(2005):Clinicalpharmacologyofrasagiline:anovel,second-generationpropargylamineforthetreatmentofParkinsondisease.JClinPharmacol45:878–894
ConnollyBS,LangAE(2014):PharmacologicaltreatmentofParkinsondisease:areview.JAMA311:1670–1683
CrosbyNJ,DeaneKH,ClarkeCE(2003):AmantadineinParkinson'sdisease.CochraneDatabaseSystRev.2003;(1):CD003468
DeaneKH,SpiekerS,ClarkeCE(2004):Catechol-O-methyltransferaseinhibitorsforlevodopa-inducedcomplicationsinParkinson'sdisease.CochraneDatabaseSystRev.2004Oct18;(4):CD00455–4
DeutscheGesellschaftfürNeurologie(2012):Parkinson-Syndrome-DiagnostikundTherapie.Internet:http://www.dgn.org/leitlinien-online-2012/inhalte-nach-kapitel/2346-ll-09-2012-parkinson-syndrome-diagnostik-und-therapie.html
European Medicines Agency (EMA) (2004): EMEA public statement on the lifting of the suspension of the marketing authorisation for tolcapone (Tasmar). Internet: www.emea.eu.int/>pdfs/human/press/pus/1185404en.pdf
European Medicines Agency (EMA) (2006): Rotigotin. Europäischer öffentlicher Beurteilungsbericht (EPAR). Internet: www.emea.eu.int/humandocs/PDFs/EPAR/neupro/>062606de1.pdf
Fahn S and the Parkinson Study Group (2005): Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 252 (Suppl 4): IV37–IV42
Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH; SP513 investigators (2007): Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22: 2398–2404
Huntington Study Group (2006): Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66: 366–372
Katzenschlager R, Sampaio C, Costa J, Lees A (2003): Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev. 2003;(2):CD003735
Lees AJ (1995): Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 311: 1602–1607
Lees AJ, Hardy J, Revesz T (2009): Parkinson's disease. Lancet 373: 2055–2066
Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y (2001): Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 57: 1687–1694
Müller-Vahl KR (2007): Die Benzamide Tiaprid, Sulpirid und Amisulprid in der Therapie des Tourette-Syndroms. Eine Standortbestimmung. Nervenarzt 78: 264–271
Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators (2009): A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361: 1268–1278
Ossig C, Reichmann H (2013): Treatment of Parkinson's disease in the advanced stage. J Neural Transm 120: 523–529
Palhagen SE, Dizdar N, Hauge T, Holmberg B, Jansson R, Linder J, Nyholm D, Sydow O, Wain- wright M, Widner H, Johansson A (2012): Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand 126: e29–33
Parkinson Study Group (2004): A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61: 561–566
Parkinson Study Group (2005): A randomized placebo-controlled trial of rasagiline in levodo- pa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62: 241–248
Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B; SP 515 Investigators (2007): Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6: 513–520
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE for The 056 Study Group (2000): A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342: 1484–1491
Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E; LARGO study group (2005): Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365: 947–954
Rascol O, Lozano A, Stern M, Poewe W (2011): Milestones in Parkinson's disease therapeutics. Mov Disord 26: 1072–1082
Schapira AH (2004): Restless legs syndrome: an update on treatment options. Drugs 64: 149–158
Scottish Intercollegiate Guidelines Network (2010): Diagnosis and pharmacological management of Parkinson's disease. A national clinical guideline. Internet: www.sign.ac.uk/pdf/>sign113.pdf
Silver DE, Ruggieri S (1998): Initiating therapy for Parkinson's disease. Neurology 50 (Suppl 6): S18–S22; discussion S44–S48
Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010): Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68: 18–27
The Parkinson Study Group (2004): Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61: 1044–1053
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2015). Parkinsonmittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2015. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47186-9_37
Download citation
DOI: https://doi.org/10.1007/978-3-662-47186-9_37
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-47185-2
Online ISBN: 978-3-662-47186-9
eBook Packages: Medicine (German Language)